Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Overview of attention for article published in Journal of Clinical Oncology, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 1 public wall post.

17/09/17-Chicago-Illinois-USA Results of Nintedanib LUME-Meso Phase 2 #mesothelioma trial reported at conference conclude that…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.